435 related articles for article (PubMed ID: 35138143)
1.
Han R; Ding L; Yang Y; Guo Y; Yin D; Wu S; Zhi P; Zhu D; Liu Q; Tan X; Zhu Y; Zhang J; Li L; Hu F
Microbiol Spectr; 2022 Feb; 10(1):e0147121. PubMed ID: 35138143
[TBL] [Abstract][Full Text] [Related]
2.
Huband MD; Mendes RE; Pfaller MA; Lindley JM; Strand GJ; Benn VJ; Zhang J; Li L; Zhang M; Tan X; Liu Q; Flamm RK
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071042
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy.
Mezzatesta ML; Trovato G; Gona F; Nicolosi VM; Nicolosi D; Carattoli A; Fadda G; Nicoletti G; Stefani S
Ann Clin Microbiol Antimicrob; 2008 Feb; 7():4. PubMed ID: 18261233
[TBL] [Abstract][Full Text] [Related]
4. Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility.
Abbey T; Vialichka A; Jurkovic M; Biagi M; Wenzler E
Microbiol Spectr; 2022 Jun; 10(3):e0054222. PubMed ID: 35647655
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii.
Seifert H; Stefanik D; Olesky M; Higgins PG
Int J Antimicrob Agents; 2020 Jan; 55(1):105829. PubMed ID: 31669740
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii.
Seifert H; Stefanik D; Sutcliffe JA; Higgins PG
Int J Antimicrob Agents; 2018 Jan; 51(1):62-64. PubMed ID: 28705668
[TBL] [Abstract][Full Text] [Related]
7. Trend of extensively drug-resistant Acinetobacter baumannii and the remaining therapeutic options: a multicenter study in Tehran, Iran over a 3-year period.
Jasemi S; Douraghi M; Adibhesami H; Zeraati H; Rahbar M; Boroumand MA; Aliramezani A; Ghourchian S; Mohammadzadeh M
Lett Appl Microbiol; 2016 Dec; 63(6):466-472. PubMed ID: 27626896
[TBL] [Abstract][Full Text] [Related]
8. Geographic patterns of carbapenem-resistant, multi-drug-resistant and difficult-to-treat Acinetobacter baumannii in the Asia-Pacific region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020.
Chen CH; Wu PH; Lu MC; Ho MW; Hsueh PR
Int J Antimicrob Agents; 2023 Feb; 61(2):106707. PubMed ID: 36608719
[TBL] [Abstract][Full Text] [Related]
9.
Karlowsky JA; Hackel MA; McLeod SM; Miller AA
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0078122. PubMed ID: 36005804
[TBL] [Abstract][Full Text] [Related]
10. Activity of the Novel Aminomethylcycline KBP-7072 and Comparators against 1,057 Geographically Diverse Recent Clinical Isolates from the SENTRY Surveillance Program, 2019.
Huband MD; Thompson JD; Gurung ND; Liu Q; Li L; Zhang J; Streit JM; Castanheira M
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0139721. PubMed ID: 34633850
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
Scheetz MH; Qi C; Warren JR; Postelnick MJ; Zembower T; Obias A; Noskin GA
Antimicrob Agents Chemother; 2007 May; 51(5):1621-6. PubMed ID: 17307973
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa.
Ahmed NH; Baba K; Clay C; Lekalakala R; Hoosen AA
BMC Res Notes; 2012 May; 5():215. PubMed ID: 22554305
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of tigecycline and comparators (2014-2016) among key WHO 'priority pathogens' and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study.
Seifert H; Blondeau J; Dowzicky MJ
Int J Antimicrob Agents; 2018 Oct; 52(4):474-484. PubMed ID: 30012439
[TBL] [Abstract][Full Text] [Related]
14. Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016-2018).
Seifert H; Blondeau J; Lucaßen K; Utt EA
J Glob Antimicrob Resist; 2022 Dec; 31():82-89. PubMed ID: 35948242
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii.
Livermore DM; Mushtaq S; Warner M; Woodford N
Antimicrob Agents Chemother; 2016 Jun; 60(6):3840-4. PubMed ID: 27044556
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of sitafloxacin against bacteremic isolates of carbapenem resistant Acinetobacter baumannii complex.
Huang YS; Wang JT; Sheng WH; Chuang YC; Chang SC
J Microbiol Immunol Infect; 2015 Oct; 48(5):545-51. PubMed ID: 24662017
[TBL] [Abstract][Full Text] [Related]
17. Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals.
Falagas ME; Skalidis T; Vardakas KZ; Voulgaris GL; Papanikolaou G; Legakis N;
Int J Antimicrob Agents; 2018 Aug; 52(2):269-271. PubMed ID: 29559273
[TBL] [Abstract][Full Text] [Related]
18. OXA-type Carbapenemases and Susceptibility of Colistin and Tigecycline Among Carbapenem-Resistant Acinetobacter Baumannii Isolates from Patients with Bacteremia in Turkey.
Cakirlar FK; Ciftci IH; Gonullu N
Clin Lab; 2015; 61(7):741-7. PubMed ID: 26299073
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.
Principe L; D'Arezzo S; Capone A; Petrosillo N; Visca P
Ann Clin Microbiol Antimicrob; 2009 May; 8():18. PubMed ID: 19460166
[TBL] [Abstract][Full Text] [Related]
20. [In vitro tigecycline and carbapenem susceptibilities of clinical Acinetobacter baumannii isolates].
Nayman Alpat S; Aybey AD; Akşit F; Ozgüneş I; Kiremitçi A; Usluer G
Mikrobiyol Bul; 2010 Oct; 44(4):641-5. PubMed ID: 21063976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
